Rigel Pharms patent expiration
1. Gavreto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10030005 | RIGEL PHARMS | Inhibitors of RET |
Nov, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(14 years from now) | |
| US11872192 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(14 years from now) | |
| US11963958 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...
Dosage: CAPSULE
More Information on Dosage
GAVRETO family patents
2. Rezlidhia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
| US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(14 years from now) | |
| US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(14 years from now) | |
| US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(14 years from now) | |
| US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(14 years from now) | |
| US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(14 years from now) | |
| US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(14 years from now) | |
| US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...
Dosage: CAPSULE
More Information on Dosage
REZLIDHIA family patents
3. Tavalisse patent
expiration
TAVALISSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8211889 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 4 months from now) | |
| US7538108 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(1 year, 6 months from now) | |
| US7989448 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 9 months from now) | |
| US8163902 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 9 months from now) | |
| US7449458 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48898 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 4 months from now) | |
| US9737554 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 4 months from now) | |
| US9266912 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 4 months from now) | |
| US8912170 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 9 months from now) | |
| US8445485 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 9 months from now) | |
| US9283238 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 9 months from now) | |
| US8652492 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2028
(4 years from now) | |
| US8263122 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2030
(6 years from now) | |
| US8951504 | RIGEL PHARMS | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(7 years from now) | |
| US8771648 | RIGEL PHARMS | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents